Ultrasound Screening Helps Prevent Stroke In Children With Sickle Cell Disease

"We studied the impact of using TCD starting in 1998, when the technique became routine at our hospital and many other centers," said Janet L. Kwiatkowski, M.D., a pediatric hematologist at The Children's Hospital of Philadelphia. Kwiatkowski presented her group's results today at a press conference during the 50th annual meeting of the American Society of Hematology.

Childhood stroke has long been known to be a devastating complication of sickle cell disease, an inherited condition in which abnormal hemoglobin deforms red blood cells into sickle-shaped bodies that do not pass smoothly through blood vessels.

TCD is a noninvasive tool that uses ultrasound waves to measure the speed of blood flow in large vessels in the brain. An abnormally high speed is a marker of a narrowed vessel, and a sign of high risk for stroke.

After the multicenter Stroke Prevention Trial in Sickle Cell Anemia showed in 1998 the utility of TCD in detecting abnormal blood speeds and the benefit of transfusions in reducing stroke risk, the Sickle Cell Program at Children's Hospital began to routinely use TCD in screening sickle cell patients. "When we see an abnormal TCD result, we treat the child with preventive blood transfusions, given regularly every three to four weeks," said Kwiatkowski.

The current study compared the rate of stroke in children with sickle cell disease in the eight years before Children's Hospital began TCD screening with the eight years from 1998 to 2006. The researchers followed 475 children in the pre-TCD group and 530 children in the post-TCD group.

In reviewing patient records, the researchers measured overt strokes, other neurological events and indeterminate events—those that could not be classified based on available information. In the pre-TCD group, there were 21 patients with overt stroke, three with other neurological events and two with indeterminate events. In contrast, the post-TCD group had two patients with overt stroke, six with other neurological events and one with an indeterminate event.

Overall, the incidence of overt stroke in the pre-TCD group was significantly higher compared to the post-TCD group—an incidence of 0.67 per 100 patient years compared to 0.06 per 100 patient years. "The study confirmed that a program of TCD screening combined with regular transfusion therapy for children found to be at high risk of stroke is effective in preventing strokes," added Kwiatkowski.

Kwiatkowski's collaborators were Kwaku Ohene-Frempong, M.D.; Kim Smith-Whitley, M.D.; Rebecca Ichord, M.D.; Henrietta Enninful-Eghan, M.S.; and Renee Moore, all of The Children's Hospital of Philadelphia. The Comprehensive Sickle Cell Program at Children's Hospital is funded through the Commonwealth of Pennsylvania Sickle Cell Program and numerous National Institutes of Health grants, and engages in basic and clinical research, public education, and a full clinical program for sickle cell disease.